27 results
6-K/A
EX-99.1
OBSVF
ObsEva SA
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance
6-K
EX-99.1
OBSVF
ObsEva SA
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance
6-K
EX-99.1
OBSVF
ObsEva SA
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
(CCO), is purpose-built to accelerate customer performance to address modern market realities. Syneos Health brings together approximately 27,000
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs … which units of account of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship
DRS
EX-4
4mn8u
14 Oct 16
Draft registration statement
12:00am
F-1
EX-4.2
5h61 c3ugked
30 Dec 16
Registration statement (foreign)
12:00am
F-3
ivr16o5x1lio1eujn
7 Aug 19
Shelf registration (foreign)
8:24am
6-K
EX-1.1
q9nrv2 nw
22 Jun 18
ObsEva Announces Launch of ProposedFollow-on Public Offering
4:06pm
6-K
EX-1.1
q0smcqy
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
kh3s aw2207bgbqgfmvy
5 Mar 21
Prospectus supplement for primary offering
7:55am
424B5
sjyq v2r9wlrv4g179
18 Jun 18
Prospectus supplement for primary offering
9:15pm
424B5
u3l7ueytysdbskx0
7 Aug 19
Prospectus supplement for primary offering
8:18am
424B5
r4y79z 5z54i0kr91
20 Jun 18
Prospectus supplement for primary offering
5:32pm
6-K
EX-99.1
oa9 5b85itnvxh
7 Aug 19
Current report (foreign)
7:21am
424B5
12ec 48xrj0gj
8 Sep 20
Prospectus supplement for primary offering
7:31am